New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
06:49 EDTACT, LCI, TEVA, MYLGeneric drug prices have risen significantly, NY Times says
The cost of some generic drugs has risen rapidly since last year, according to The New York Times, which cited information from research firm EvaluatePharma. Publicly traded generic drug companies include Teva (TEVA), Mylan (MYL), Actavis (ACT) Impax Laboratories (IPXL), and Lannett (LCI). Reference Link
News For TEVA;MYL;ACT;LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 27, 2014
18:34 EDTMYLMedicines Co. wins patent suit against Mylan, Bloomberg reports
The Medicines Co. (MDCO) has won a patent suit against Mylan (MYL), Bloomberg reports. A U.S. district court found that Mylan infringed the Medicines Co. patent for its blood-clot-inhibiting drug Angiomax. Shares of Medicines Co. are up 11.5% to $24.76 following the report. Reference Link
15:18 EDTACTEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
12:44 EDTMYLStocks with call strike movement; CELG MYL
Celgene (CELG) April 115 call option implied volatility increased 4% to 30, Mylan (MYL) April 60 call option implied volatility increased 3% to 29 according to IVolatility.
10:36 EDTACTAllergan delivers earnings beat, says willing to consider higher Valeant bid
Subscribe for More Information
07:22 EDTTEVAAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
08:15 EDTMYLPfizer wins SUTENT patent case In Delaware District Court
Pfizer (PFE) announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. Pfizer filed suit in June 2010 after Mylan (MYL) applied to the U.S. Food and Drug Administration to market a generic version of SUTENT prior to the expiration of the patents covering sunitinib malate and its uses. After a four-day trial, the Court agreed that Mylan infringed the valid patents covering SUTENT.
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
07:56 EDTLCILannett sees Q1 EPS 91c-94c, consensus 77c
Subscribe for More Information
06:22 EDTMYLMylan, Abbott enter into amendment, still see deal closing in 1Q15
Subscribe for More Information
October 22, 2014
11:59 EDTMYLStocks with call strike movement; MYL AMZN
Subscribe for More Information
09:16 EDTMYLAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
October 21, 2014
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
08:04 EDTMYLGerman fund pressured to sell Mylan stake over drug used in executions, FT says
Subscribe for More Information
07:20 EDTMYLInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
06:28 EDTTEVA, ACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use